# Sinorda

Source: https://onco.cc/companies/sinorda/  
OnCo record `sinorda` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sinorda is a Chinese drug company, already selling a stomach-acid medicine, that is testing a cell therapy made from a patient's own T cells taken from the lymph nodes nearest the tumour.

## Summary

Guizhou Sinorda Pharmaceutical Co., Ltd. (生诺医药), in the Guiyang national high-tech zone, was founded in 2010 according to the company and is a commercial-stage company focused on digestive disease, tumour immunology and autoimmune disease; its acid-related disease drug linaprazan glurate (X842) is approved in China. In oncology, its Lymph-T Exp platform expands tumour-reactive T cells from sentinel lymph nodes, which the company says has investigator-initiated clinical results in several tumours. SND002 Cell Injection, an autologous T cell product, is in a phase 1 study in advanced solid tumours including colorectal and gastric cancer (NCT07903857). Its first registered cancer trial, NCT07903857, was posted on ClinicalTrials.gov in October 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Guizhou Sinorda Pharmaceutical Co., Ltd.; Guizhou Sinorda Biomedicine; 生诺医药
- HQ: Guiyang
- Type: pharma
- Website: https://www.sinorda.com/

## Notes

- Company website (Chinese) read on 29 October 2026. Oncology is one of three focus areas; the company was kept because SND002 is its own cell therapy. The TIL therapy technology tag is the nearest fit for lymph-node-derived T cells. No financing amounts read.

## Sources

- Official website: https://www.sinorda.com/
- About: https://www.sinorda.com/About.html
- ClinicalTrials.gov: phase 1 trial of SND002 (NCT07903857): https://clinicaltrials.gov/study/NCT07903857

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [TIL therapy](https://onco.cc/technologies/til-therapy/)

---
JSON: https://onco.cc/api/v1/entities/sinorda.json